• Immuneering is enrolling a Phase 3 trial of atebimetinib with modified chemotherapy in first-line pancreatic cancer; topline results are expected mid-2028.
• Phase 2 data presented at ASCO showed median overall survival of 17.3 months; an update is expected in the first half of 2027.
• An Astellas collaboration targets CLDN18.2-positive pancreatic cancer with atebimetinib combinations, including chemotherapy-free regimens.
• The pipeline also includes Phase 2 lung cancer combinations with Regeneron and Eli Lilly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.